CL2015001660A1 - Composicion farmaceutica oral de accion prolongada (pap) que comprende un compuesto derivado de betulina en forma de microparticulas y encapsulado en un polimero, y un sistema tensoactivo que comprende un tensoactivo, un estabilizador y una sal amortiguadora; metodo para la prevencion y el tratamiento de una infeccion por vih. - Google Patents

Composicion farmaceutica oral de accion prolongada (pap) que comprende un compuesto derivado de betulina en forma de microparticulas y encapsulado en un polimero, y un sistema tensoactivo que comprende un tensoactivo, un estabilizador y una sal amortiguadora; metodo para la prevencion y el tratamiento de una infeccion por vih.

Info

Publication number
CL2015001660A1
CL2015001660A1 CL2015001660A CL2015001660A CL2015001660A1 CL 2015001660 A1 CL2015001660 A1 CL 2015001660A1 CL 2015001660 A CL2015001660 A CL 2015001660A CL 2015001660 A CL2015001660 A CL 2015001660A CL 2015001660 A1 CL2015001660 A1 CL 2015001660A1
Authority
CL
Chile
Prior art keywords
surfactant
betulin
pap
microparticles
encapsulated
Prior art date
Application number
CL2015001660A
Other languages
English (en)
Spanish (es)
Inventor
Brian Alvin Johns
Shenshen Cai
Andrew Spaltenstein
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CL2015001660A1 publication Critical patent/CL2015001660A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CL2015001660A 2012-12-14 2015-06-12 Composicion farmaceutica oral de accion prolongada (pap) que comprende un compuesto derivado de betulina en forma de microparticulas y encapsulado en un polimero, y un sistema tensoactivo que comprende un tensoactivo, un estabilizador y una sal amortiguadora; metodo para la prevencion y el tratamiento de una infeccion por vih. CL2015001660A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737177P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
CL2015001660A1 true CL2015001660A1 (es) 2015-10-02

Family

ID=50935020

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001660A CL2015001660A1 (es) 2012-12-14 2015-06-12 Composicion farmaceutica oral de accion prolongada (pap) que comprende un compuesto derivado de betulina en forma de microparticulas y encapsulado en un polimero, y un sistema tensoactivo que comprende un tensoactivo, un estabilizador y una sal amortiguadora; metodo para la prevencion y el tratamiento de una infeccion por vih.

Country Status (20)

Country Link
US (2) US9795619B2 (2)
EP (1) EP2931285A4 (2)
JP (1) JP2016503030A (2)
KR (1) KR20150093819A (2)
CN (1) CN104902905A (2)
AU (1) AU2013358897B2 (2)
BR (1) BR112015013695A2 (2)
CA (1) CA2893959A1 (2)
CL (1) CL2015001660A1 (2)
CR (1) CR20150313A (2)
EA (1) EA201590862A1 (2)
HK (1) HK1209638A1 (2)
IL (1) IL238807A0 (2)
MA (1) MA38182A1 (2)
MX (1) MX2015007563A (2)
PE (1) PE20151326A1 (2)
PH (1) PH12015501156A1 (2)
SG (2) SG10201704467SA (2)
WO (1) WO2014093941A1 (2)
ZA (1) ZA201503594B (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
SG10201704467SA (en) * 2012-12-14 2017-06-29 Glaxosmithkline Llc Pharmaceutical compositions
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
NO2865735T3 (2) 2013-07-12 2018-07-21
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
NO2717902T3 (2) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
EP3197430A1 (en) 2014-09-26 2017-08-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long acting pharmaceutical compositions
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
US10370405B2 (en) 2015-03-16 2019-08-06 Hetero Labs Limited C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018042331A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US11564921B2 (en) 2017-07-21 2023-01-31 Viiv Healthcare Company Regimens for treating HIV infections and AIDS

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
EP1292562A1 (en) 2000-05-23 2003-03-19 Univerzita palackeho V Olomouci Triterpenoid derivatives
US7163700B2 (en) * 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
WO2005112929A2 (en) * 2004-05-20 2005-12-01 Cornell Research Foundation, Inc. Anti-hiv-1 activity of betulinol derivatives
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
CN1682740A (zh) * 2005-03-11 2005-10-19 中国药科大学 五环三萜类化合物在制备糖原磷酸化酶抑制剂中的应用
EP1869063A2 (en) 2005-03-29 2007-12-26 Regents Of The University Of Minnesota Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Hiv-感染之預防
WO2006117666A2 (en) * 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
EP1986654A2 (en) 2006-02-21 2008-11-05 Achillion Pharmaceuticals, Inc. Substituted taraxastanes useful for treating viral infections
FI121468B (fi) 2006-06-07 2010-11-30 Valtion Teknillinen Betuliiniperäiset yhdisteet antimikrobisina aineina
CN101478950B (zh) 2006-06-23 2013-02-06 泰博特克药品有限公司 Tmc278的水性悬浮液
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
CA2668452A1 (en) 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
CA2693044C (en) * 2007-07-12 2017-03-14 Tibotec Pharmaceuticals Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
EP2240504A1 (en) * 2008-01-03 2010-10-20 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
CA2711424A1 (en) 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
DE102008037025C5 (de) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
CZ301318B6 (cs) 2008-11-13 2010-01-13 Univerzita Palackého v Olomouci 2-Deoxyglykosidy triterpenoidu, zpusob jejich prípravy a jejich použití jako lécivo
KR101733625B1 (ko) * 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 hiv 인테그라제 억제제 및 중간체의 합성
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
WO2011100308A1 (en) * 2010-02-11 2011-08-18 Glaxosmithkline Llc Derivatives of betulin
TWI577377B (zh) * 2010-09-16 2017-04-11 Viiv醫療保健公司 醫藥組合物
WO2013020246A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Methylene derivatives of betulin
WO2013020245A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Carbonyl derivatives of betulin
BR112014014046A2 (pt) 2011-12-14 2017-06-13 Glaxosmithkline Llc composto, composição, e, método para tratar hiv
JO3387B1 (ar) * 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
WO2014035945A1 (en) 2012-08-28 2014-03-06 Glaxosmithkline Llc Pharmaceutical compositions
SG10201704467SA (en) * 2012-12-14 2017-06-29 Glaxosmithkline Llc Pharmaceutical compositions
EP3197430A1 (en) 2014-09-26 2017-08-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long acting pharmaceutical compositions

Also Published As

Publication number Publication date
PH12015501156A1 (en) 2015-08-10
CR20150313A (es) 2015-10-19
AU2013358897A1 (en) 2015-07-02
US20150313917A1 (en) 2015-11-05
SG10201704467SA (en) 2017-06-29
CA2893959A1 (en) 2014-06-19
WO2014093941A1 (en) 2014-06-19
US9795619B2 (en) 2017-10-24
ZA201503594B (en) 2018-11-28
MX2015007563A (es) 2015-10-14
AU2013358897B2 (en) 2017-01-05
EP2931285A4 (en) 2016-06-01
CN104902905A (zh) 2015-09-09
SG11201503807TA (en) 2015-06-29
HK1209638A1 (en) 2016-04-08
EP2931285A1 (en) 2015-10-21
EA201590862A1 (ru) 2016-05-31
PE20151326A1 (es) 2015-10-12
BR112015013695A2 (pt) 2017-07-11
IL238807A0 (en) 2015-06-30
US20180042944A1 (en) 2018-02-15
JP2016503030A (ja) 2016-02-01
MA38182A1 (fr) 2018-04-30
KR20150093819A (ko) 2015-08-18

Similar Documents

Publication Publication Date Title
CL2015001660A1 (es) Composicion farmaceutica oral de accion prolongada (pap) que comprende un compuesto derivado de betulina en forma de microparticulas y encapsulado en un polimero, y un sistema tensoactivo que comprende un tensoactivo, un estabilizador y una sal amortiguadora; metodo para la prevencion y el tratamiento de una infeccion por vih.
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
CL2015000487A1 (es) Compuestos derivados de sulfamoilarilamidas; composicion farmaceutica que los comprende, util para la prevencion o tratamiento de una infeccion por el virus de la hepatitis b (vhb).
CL2014000468A1 (es) Compuestos derivados del acido 2-oxo-6-(fenil/heteroaril)l-1,2-dihidropiridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para el alivio de una infeccion bacteriana.
MX2016009337A (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
CL2014000919A1 (es) Compuestos derivados de acido 2-tert-butoxi-2-(5-metilbenzo[d]tiazol-6-il) acetico; composicion farmaceutica que los comprende; metodo para tratar una infeccion por vih; y su uso para tratar una infeccion por vih.
CL2014000601A1 (es) Composición tópica veterinaria que comprende al menos un agente activo derivado de isoxazolina; y uso de la composición para el tratamiento o prevención de una infestación o infección por parásitos en un animal.
ME03323B (me) Paraziticidne oralne veterinarske kompozicije koje sadrže sistemski djelujuća aktivna sredstva, metodi i primjene istih
CL2013003650A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo anti leucocidina luke y un portador farmaceuticamente aceptable.
PE20140255A1 (es) Tableta dispersable en forma oral
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
BR112014025726A2 (pt) mecanismo, sistema e método para tratamento endodôntico
CL2014001585A1 (es) Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih.
CL2014002053A1 (es) Composición pesticida que comprende un compuesto derivado de una hidrazinacarbotioamida; y proceso de aplicación.
BR112014001274A2 (pt) composto de hormônio luteinizante, e, composição farmacêutica
MX375417B (es) Uso de ácido (r)-2-[3-[[n-(benzoxazol-2-il)-n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico o una sal, o solvato del mismo para el tratamiento de la esteatosis hepática no alcohólica, supresión de la deposición de grasa en el hígado, y en la reducción de células de kupffer en el hígado.
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2015000732A1 (es) Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.
BR112014025041B8 (pt) Composição farmacêutica
BR112013010738A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção viral
CL2014003012A1 (es) Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c.
LT3324948T (lt) Daugiasluoksnės farmaciniu požiūriu aktyvaus junginio atpalaidavimo mikrodalelės skystoje vaisto formoje
LT2939665T (lt) Farmacinė kompozicija, skirta živ infekcijų gydymui